Drug Trial Radar · NCT07873229
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Mar 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- EccogeneIndustry
- Sponsor type
- Industry
- First posted
- Oct 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK) of metformin (a MATE1/2-K probe substrate), midazolam (a CYP3A4 probe substrate), and caffeine (a CYP1A2 probe substrate).
Conditions
- Steatohepatitis, Nonalcoholic
- Osteo Arthritis
Interventions
ECC0509Drug
ECC0509 will be administered orally.
MetforminDrug
Metformin will be administered orally.
CaffeineDrug
Caffeine will be administered orally.
MidazolamDrug
Midazolam will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum plasma concentration of metformin in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 6 and 7
- Time to maximum plasma concentration of metformin in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 6 and 7
- Area under the drug concentration-time curve of metformin in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 6 and 7
- Clearance of metformin in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of sulfasalazine will be collected on Days 1, 2, 6 and 7
- Maximum plasma concentration of caffeine and midazolam in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 16 and 17
- Time to maximum plasma concentration of caffeine and midazolam in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 16 and 17
- Area under the drug concentration-time curve of caffeine and midazolam in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 16 and 17
- Clearance of caffeine and midazolam in the blood of participants who have taken ECC0509 (as part of called pharmacokinetic or 'PK' testing)Time frame: Blood samples for PK testing of pitavastatin will be collected on Days 1, 2, 16 and 17
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.